Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these tre...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e2e3c987d9e84ccb9b7c66bef2e582d6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e2e3c987d9e84ccb9b7c66bef2e582d6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e2e3c987d9e84ccb9b7c66bef2e582d62021-12-02T16:43:56ZPatients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion10.1038/s41467-020-17703-62041-1723https://doaj.org/article/e2e3c987d9e84ccb9b7c66bef2e582d62020-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-17703-6https://doaj.org/toc/2041-1723Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.David SimonKoray TascilarGerhard KrönkeArnd KleyerMario M. ZaissFranz HepptChristine MederRaja AtreyaEntcho KlenskePeter DietrichAbdullah AbdullahThorsten KliemGiulia CorteHarriet MorfMoritz LeppkesAndreas E. KremerAndreas RammingMilena PachowskyFlorian SchuchMonika RonnebergerStefan KleinertClara MaierAxel J. HueberKarin MangerBernhard MangerCarola BerkingMatthias TenbuschKlaus ÜberlaMichael SticherlingMarkus F. NeurathGeorg SchettNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-7 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| description |
Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19. |
| format |
article |
| author |
David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett |
| author_facet |
David Simon Koray Tascilar Gerhard Krönke Arnd Kleyer Mario M. Zaiss Franz Heppt Christine Meder Raja Atreya Entcho Klenske Peter Dietrich Abdullah Abdullah Thorsten Kliem Giulia Corte Harriet Morf Moritz Leppkes Andreas E. Kremer Andreas Ramming Milena Pachowsky Florian Schuch Monika Ronneberger Stefan Kleinert Clara Maier Axel J. Hueber Karin Manger Bernhard Manger Carola Berking Matthias Tenbusch Klaus Überla Michael Sticherling Markus F. Neurath Georg Schett |
| author_sort |
David Simon |
| title |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_short |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_fullStr |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full_unstemmed |
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_sort |
patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of sars-cov-2 seroconversion |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/e2e3c987d9e84ccb9b7c66bef2e582d6 |
| work_keys_str_mv |
AT davidsimon patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT koraytascilar patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT gerhardkronke patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT arndkleyer patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT mariomzaiss patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT franzheppt patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT christinemeder patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT rajaatreya patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT entchoklenske patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT peterdietrich patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT abdullahabdullah patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT thorstenkliem patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT giuliacorte patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT harrietmorf patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT moritzleppkes patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT andreasekremer patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT andreasramming patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT milenapachowsky patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT florianschuch patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT monikaronneberger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT stefankleinert patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT claramaier patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT axeljhueber patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT karinmanger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT bernhardmanger patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT carolaberking patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT matthiastenbusch patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT klausuberla patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT michaelsticherling patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT markusfneurath patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT georgschett patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion |
| _version_ |
1718383545541459968 |